Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DENN domain-containing protein 1B (DENND1B) is a guanine nucleotide exchange factor (GEF) that activates the small GTPase RAB35, acting primarily in clathrin-mediated endocytosis and endocytic recycling[1][5][7]. It regulates internalization of the T-cell receptor in T helper 2 (TH2) lymphocytes, thereby modulating cytokine production and immune responses[5]. Genetic association studies implicate DENND1B variants in susceptibility to childhood asthma and obesity in both humans and dogs, potentially through effects on energy balance and melanocortin 4 receptor trafficking[1][5][8]. The protein acts as an adapter linking RAB35 activation to clathrin-coated endocytic vesicles and the AP2 adapter complex, playing a key role in vesicular trafficking in immune and other cells[1][5][7]. While DENND1B is not the direct target of approved drugs, its pathway modulation could have relevance for disease risk and therapy in immune and metabolic disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DENN domain-containing protein 1B (DENND1B).